Overview

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
An open-label, randomised, controlled, multi-centre, trial with disease free survival as the primary end point. The worldwide collaboration is referred to as GLOBAL BALLAD and consists of a number of individual parallel prospective studies addressing the same objectives with similar designs brought together under the framework of the International Rare Cancer Initiative. This protocol is for BALLAD BELGIUM, which is the component of GLOBAL BALLAD.
Phase:
Phase 3
Details
Lead Sponsor:
Belgian Group of Digestive Oncology
Collaborators:
Cancer Research UK
Kom Op Tegen Kanker
Treatments:
Capecitabine
Oxaliplatin